Serum Glial Fibrillary Acidic Protein as a Diagnostic Biomarker in Dogs with Progressive Myelomalacia

Journal of Veterinary Medical Science

Jun YASUDA³  Yasuhiko OKAMURA¹  Tadahisa MASHITA³  Yasunori SATO³  Reeko SATO³  Saori KOBAYASHI³  Shunsuke SHIMAMURA³  Yuji UZUKA¹  Masaaki KATAYAMA¹  Hiroaki KAMISHINA² 

[1] Division of Small Animal Surgery, Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka 020–8550, Japan;Division of Veterinary Clinical Radiology, Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu 501–1193, Japan;Division of Small Animal Internal Medicine, Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka 020–8550, Japan

关键词: canine;    diagnosis;    glia;    neurology;   

DOI  :  10.1292/jvms.12-0483

学科分类：兽医学

来源: Japanese Society of Veterinary Science

【 摘 要 】

References(17)Cited-By(5)In humans, increased levels of GFAP in the CSF and blood have been reported with various neural diseases. However, there has been no study describing the usefulness of GFAP in the blood for disease of the spinal cord in dogs. The aim of this study was to describe the utility of GFAP in serum for a diagnosis of progressive myelomalacia. Fifty-six dogs with acute thoracolumbar IVDD diagnosed by computed tomography with myelography or MRI were included. Serum specimens were collected at initial presentation from all cases and at follow-up examinations from some cases. Serum samples were assayed for GFAP concentrations using a commercially available GFAP ELISA Kit. Progressive myelomalacia was the final diagnosis in 8/51 cases (15.6%). Eight dogs had clinical signs suggestive of progressive myelomalacia, of which 6 were positive and 2 were negative by GFAP. Seven dogs had a detectable level of serum GFAP, of which 6 had the onset of progressive myelomalacia. The sensitivity and specificity of the GFAP to progressive myelomalacia were 75% and 97.7%, respectively. The results suggest the utility of GFAP in serum in the diagnosis of progressive myelomalacia.

【 授权许可】

Unknown